2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
65
Neoplasm Metastasis
6
Prostatic Neoplasms, Castration-Resistant
5
Non-metastatic Castration-resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
3
Neoplasms
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Hormone-sensitive Prostate Cancer
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Adenocarcinoma
2
Urogenital Diseases
1
Thrombocytosis
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-metastatic Prostate Cancer
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Interventions
Tamoxifen
4
Exercise
3
pyrotinib
2
abemaciclib
2
Paclitaxel
2
Metformin
2
Letrozole
2
Cyclophosphamide
2
Control Groups
2
Capecitabine
2
Bupivacaine
2
Aromatase Inhibitors
2
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
palbociclib
1
iniparib
1
exemestane
1
durvalumab
1
darolutamide
1
Yoga
1
Waiting Lists
1
Vitamin D
1
Tumor Burden
1
Tretinoin
1
Trastuzumab
1
Tocopherols
1
Thioctic Acid
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Cancer Female
×
darolutamide
×
Clear all
NCT03383679
2022-11-21
START
UNICANCER
Phase 2
Completed
94 enrolled